# An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease

> **NCT02566889** · PHASE4 · TERMINATED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 53 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT02566889
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Study was terminated due to the inability to enroll a sufficient number of the required subject population
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566889, "An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02566889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*